VFC resolution update : hepatitis A vaccines by Whitlatch, Frank et al.
VFC Resolution Update:
Hepatitis A Vaccines
Frank Whitlatch
Immunization Services Division
National Center for Immunization and 
Respiratory Diseases
June 27, 2019
Note
 Yellow font/highlight in the presentation is used 
to indicate changes to the resolution in 
comparison to the prior approved version.
Purpose of the Resolution
 The purpose of this resolution is to streamline 
the Recommended Vaccination Schedule and 
Intervals section, update the language related to 
catch-up vaccination, add information about the 
accelerated Twinrix schedule, clarify the timing 
of vaccine and immunoglobulin receipt, and 
remove pregnancy as a precaution.
Eligible Groups
Infants 6-11 months of age traveling to countries outside of 
the United States for which protection against hepatitis A is 
recommended. 
All children aged 1 through 18 years of age. 
Recommended Vaccination Schedule
 All children should receive hepatitis A vaccine at 1 year of age (i.e., 
12-23 months). Vaccination should be completed according to the 
licensed schedules below. 
 Catch up is recommended for all unvaccinated children and 
adolescents aged 2-18 years. Children and adolescents who have 
not previously received HepA vaccine should be vaccinated 
routinely at any age. 
1.  Use of brand names is not meant to preclude the use of other hepatitis A vaccines where 
appropriate.
2.  0 months represents timing of the initial dose; subsequent numbers represent months after 
the initial dose.
3. Only persons 18 years of age are eligible to receive Twinrix through the VFC program.
Vaccine1 Age # of 
Doses
Schedule2
Havrix (pediatric formulation) 1 year 2 doses 0, 6-12 months
Vaqta (pediatric formulation) 1 year 2 doses 0, 6-18 months
Twinrix (adult formulation)3 18 years 3 or 4
doses
• 0, 1, 6 months;
• 0, 7 days, 21-30 days, 12 
months (accelerated 
schedule)
Recommendation for Use of Hepatitis A 
Vaccine for Post-Exposure Prophylaxis
Healthy persons aged 12 months through 18 
years, who have been exposed to HAV within the 
prior 14 days and have not received hepatitis A 
vaccine previously should receive a single dose of 
hepatitis A vaccine as soon as possible.  The 
hepatitis A vaccine series can be completed with 
the second dose at least 6 months after the first 
dose. 
Selected Special Categories
 A single dose of hepatitis A vaccine should be administered to 
infants age 6-11 months of age traveling to countries outside 
the United States for which protection against hepatitis A is 
recommended on CDC’s Traveler’s health website 
(https://wwwnc.cdc.gov/travel/). Infants should then receive 
the full 2-dose hepatitis A vaccine series at ≥12 months of age 
as recommended. 
 Persons administered IG for whom hepatitis A vaccine is also 
recommended should receive a dose of vaccine 
simultaneously with IG. If only IG or only vaccine is available, 
either available product should be administered as soon as 
possible. For persons who receive vaccine, the second dose 
should be administered according to the licensed schedule to 
complete the series.  The efficacy of IG or vaccine when 
administered >2 weeks after exposure has not been 
established.
Recommended Dosage and 
Contraindications/Precautions
Recommended Dosage
Refer to product package inserts.
Contraindications and Precautions
The following conditions are contraindications to the administration of hepatitis A vaccine:
1.  Allergy to vaccine components
-Anaphylactic reaction to the vaccine or a constituent of the vaccine
2.  Acute, moderate, or severe illness with or without a fever
Statement Regarding Update Based on 
Published  Documents
 [If an ACIP recommendation regarding hepatitis 
A vaccination is published within 6 months 
following this resolution, the relevant language 
above (except in the eligible groups sections) 
will be replaced with the language in the 
recommendation and incorporated by reference 
to the URL.]
